Precision Genome Editing Unveils a Breakthrough in Reversing Antibiotic Resistance: CRISPR/Cas9 Targeting of Multi-Drug Resistance Genes in Methicillin-Resistant

Aysegul Ates,Cihan Tastan,Safak Ermertcan

DOI: https://doi.org/10.1101/2023.12.31.573511

2024-01-01

Abstract:Antibiotic resistance poses a global health crisis, limiting the efficacy of available therapeutic agents and hindering the development of new antibiotics. The pharmaceutical industry’s waning interest in antibiotic production further exacerbates this challenge. Addressing antibiotic resistance demands innovative solutions. Here, we explore the application of CRISPR-Cas-based antimicrobials as a pioneering approach to combat multidrug resistance. Our study focuses on the methicillin-resistant clinical Staphylococcus aureus (MRSA), a significant clinical threat. Utilizing CRISPR/Cas9 technology, we aimed to concurrently target methicillin (mecA), gentamicin (aacA), and ciprofloxacin (grlA, grlB) resistance genes, thereby altering the resistance profile and enhancing sensitivity to antibiotics. We engineered CRISPR plasmids containing sgRNAs specific to the target regions, which were subsequently electroporated into MRSA strains. Real-time Polymerase Chain Reaction (RT-PCR) assessed changes in resistance gene expression, while disk diffusion and broth microdilution methods determined alterations in resistance status. Western blotting analyzed changes in PBP2a expression, and Sanger sequence analysis confirmed mutations in target regions. Results revealed a statistically significant 1.5-fold decrease in mecA gene expression, 5.5-fold decrease in grlA gene, 6-fold decrease in grlB gene, and 4-fold decrease in aacA gene compared to the wild type strain, as determined by RT-PCR. Antibiotic susceptibility tests demonstrated the suppression of mecA, grlA, grlB, and aacA genes, resulting in the reversal of resistance to beta-lactam, quinolone, and aminoglycoside antibiotics. Western blot analysis showed 70% decrease in PBP2a expression, indicating the breakdown of beta-lactam resistance. Sanger sequence analysis confirmed point mutations in grlB and aacA genes, along with three-base mutations in grlA and mecA genes. Our findings underscore the potential of CRISPR/Cas9 technology to mitigate antibiotic resistance, offering a transformative strategy to restore the efficacy of existing antibiotics in the face of multidrug-resistant pathogens.

Microbiology

What problem does this paper attempt to address?

### Problems the Paper Aims to Solve

This paper aims to address the global health crisis of antibiotic resistance. Specifically, the research team utilizes CRISPR/Cas9 technology to target multiple resistance genes in methicillin-resistant Staphylococcus aureus (MRSA), including the *mecA* gene encoding β-lactam antibiotic resistance, the *aacA* gene encoding gentamicin resistance, and the *grlA* and *grlB* genes encoding ciprofloxacin resistance. By targeting these genes, the researchers hope to alter the resistance profile of MRSA and increase its sensitivity to antibiotics.

### Main Findings
1. **Changes in Gene Expression**: Compared to the wild-type (WT) strain, the knockout (KO) strain showed a significant reduction in the expression of the *mecA* gene by 1.5 times, the *grlA* gene by 5.5 times, the *grlB* gene by 6 times, and the *aacA* gene by 4 times.
2. **Antibiotic Sensitivity Testing**: In both disk diffusion and broth dilution methods, the KO strain showed significantly increased sensitivity to multiple antibiotics (such as cefoxitin, ciprofloxacin, and gentamicin), with a substantial decrease in MIC values.
3. **Changes in Protein Expression**: Western blot analysis showed a 70% reduction in the expression of the PBP2a protein, further validating the effectiveness of the *mecA* gene knockout.
4. **Sequence Analysis**: Sanger sequencing results showed point mutations in the target regions, confirming the success of CRISPR/Cas9-mediated gene editing.

### Conclusion
This study demonstrates the great potential of CRISPR/Cas9 technology in reversing the multidrug resistance of MRSA, restoring the effectiveness of existing antibiotics, and providing a new strategy to combat multidrug-resistant pathogens.